Overview

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

Status:
Completed

Trial end date:
2006-10-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to determine the efficacy and safety of ciclesonide nasal spray in children with seasonal allergic rhinitis. Ciclesonide will be administered intranasally at two dose levels once daily. The study consists of a baseline period (1 to 3 weeks) and a treatment period (2 weeks).

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Ciclesonide